Credit : Google

For uncontrolled Type 2 Diabetes, Glenmark introduces lobeglitazone for the first time

Credit : Google

Glenmark Pharmaceuticals Ltd. declared that it was the first company to introduce Thiazolidinedione Lobeglitazone for the treatment of type 2 diabetes in adults

Credit : Google

The company claims that the medication will be sold under the brand name LOBG and that it contains lobeglitazone (0.5 mg).

Credit : Google

To help adult diabetic patients with glycemic control, the medication is to be taken once daily as directed by a doctor.

Credit : Google

LOBG is a desirable therapeutic option for treating Type 2 diabetes in people who are insulin resistant

Credit : Google

The manufacturing and commercialization of Lobeglitazone was previously approved by the Indian drug authority

Credit : Google

the results of this experiment showed that Lobeglitazone provided quicker and better glycemic management.

Credit : Google

A new and cost-effective medicine that will aid in addressing insulin resistance among adult patients

Credit : Google

An anti-diabetic medication called lobeglitazone acts as an insulin sensitizer, increasing the receptivity of human cells to insulin.